Description

Technical Parameters

Introduction

raws

product-1400-1400

Products Description

#### **1. Introduction**

Pregabalin is a γ-aminobutyric acid (GABA) analogue developed by Pfizer and approved by the FDA in 2004. It is widely used to treat neuropathic pain, epilepsy and generalized anxiety disorder. Its raw materials (Raws Powder) are the core components of drug preparations, and their quality directly affects the safety and efficacy of finished drugs. This article systematically explains the chemical properties, classification, preparation process, application and market prospects.

#### **2. Chemical properties and basic information**

- **Chemical name**: (S)-3-(aminomethyl)-5-methylhexanoic acid

- **CAS number**: 148553-50-8

- **Molecular formula**: C₈H₁₇NO₂

- **Molecular weight**: 159.23 g/mol

- **Structural formula**: Stereoselective (S-configuration), more active than R-isomer.

- **Solubility**: Soluble in water and methanol, slightly soluble in ethanol.

- **Stability**: Sensitive to light and heat, needs to be sealed and stored away from light.

#### **3. Classification of pregabalin APIs**

Based on purity, use and preparation process, pregabalin APIs can be divided into the following categories:

##### **1. Classification by purity grade**

- **Pharmaceutical Grade**

- **Purity**: ≥99.5%, in line with USP/EP pharmacopoeia standards.

- **Advantages**: Low impurities (such as heavy metals <10ppm), suitable for high-end preparations such as injections and capsules.

- **Application**: Clinical therapeutic drug production.

- **Industrial Grade**

- **Purity**: 95%-99%, used in non-direct medicinal scenarios.

- **Advantages**: Low cost, suitable for research or intermediate synthesis.

- **Risk**: Impurities may affect the efficiency of subsequent reactions.

##### **2. Classification by synthesis route**

- **Chemical synthesis method**

- **Route A**: Starting from isoprene, it is generated through epoxidation, Gabriel reaction and other steps.

- **Advantages**: The process is mature and suitable for large-scale production.

- **Disadvantages**: Using toxic reagents such as cyanide, the environmental pressure is high.

- **Biocatalysis method**

- **Technology**: Using enzyme catalysis (such as transaminase) to achieve chiral synthesis.

- **Advantages**: High stereoselectivity and green environmental protection.

- **Representative process**: Patented technology (such as Codexis' enzyme engineering route).

- **Chiral separation method**

- **Method**: Separation of S/R isomers by chromatography or crystallization.

- **Application**: Early production, now mostly replaced by asymmetric synthesis.

##### **3. Classification by dosage form requirements**

- **Micronized raw materials**: Particle size ≤10μm, improve solubility, used for oral rapid release preparations.

- **Coating raw materials**: Premixed sustained-release excipients for controlled-release tablets.

#### **4. Advantages of pregabalin API**

1. **High efficiency**:

- High affinity binding to the α2-δ subunit of neuronal calcium channels, quickly relieving neuralgia.

2. **Safety**:

- Metabolism is not dependent on liver enzymes, and the risk of drug interactions is low.

3. **Stability**:

- The API can be stable for more than 2 years when sealed and stored at 25°C.

4. **Process flexibility**:

- Multiple synthetic routes to meet different production capacity requirements.

#### **5. Market application and formulation type**

- **Antiepileptic drugs**: Adjunctive treatment of partial seizures (such as Lyrica®).

- **Neuropathic pain**: Diabetic neuropathy, postherpetic pain.

- **Psychiatry**: Second-line treatment of generalized anxiety disorder (GAD).

- **Emerging research**: Potential applications in fibromyalgia and alcohol withdrawal syndrome.

#### **6. Key technologies for synthesis process**

1. **Asymmetric synthesis**:

- Use chiral catalysts (such as BINAP-Ru) to directly generate S-isomers with a yield of >90%.

2. **Green chemistry improvement**:

- "One-pot" reaction with water as solvent to reduce waste emissions.

3. **Continuous flow technology**:

- Microreactor improves mass transfer efficiency and shortens production cycle.

#### **7. Quality control and regulatory requirements**

- **Pharmacopoeia standards**:

- USP-NF: Detect related substances (such as intermediates, degradation products).

- EP: Residual solvents are required (such as toluene ≤890ppm).

- **Analytical methods**:

- HPLC (chiral column method) ensures optical purity >99%.

- ICP-MS detects heavy metals (lead, arsenic, etc.).

#### **8. Storage and transportation specifications**

- **Conditions**:

- Temperature: 2-8℃ (long term) or room temperature (short term).

- Humidity: ≤60% RH, moisture-proof and light-proof.

- **Packaging**:

- Aluminum foil bag vacuum packaging, external shockproof wooden box.

#### **9. Market prospects and challenges**

- **Growth drivers**:

- Global increase in neuropathic pain patients (estimated to reach 500 million in 2030).

- Patent expiration drives the generic drug market (Lyrica® global sales of US$2.8 billion in 2022).

- **Challenges**:

- Strict regulations (such as FDA's DMF file review).

- Environmental pressure forces companies to upgrade biosynthesis processes.

#### **10. Conclusion**

As a high-value-added API, the quality and process innovation of pregabalin API are the core of competition. Future trends will focus on green synthesis, continuous manufacturing and indication expansion to provide better solutions for the treatment of chronic diseases.